Published April 29, 2022
0 views Journal article Open Access Open Access

A Phase II Study on the Effect of Taurisolo® Administered via AEROsol in Hospitalized Patients with Mild to Moderate COVID-19 Pneumonia: The TAEROVID-19 Study.

Creators

  • 1. Pneumology I and Respiratory Pathophysiology Unit, Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", A. Cardarelli Hospital, 80131 Naples, Italy.
  • 2. Pneumology I and Respiratory Pathophysiology Unit, Department of Clinical Medicine and Surgery, Section of Respiratory Disease, University Federico II, A. Cardarelli Hospital, 80131 Naples, Italy.
  • 3. Infectious Diseases Unit, Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy.
  • 4. Department of Clinical Medicine and Surgery, Section of Respiratory Diseases, University Federico II, Azienda Ospedaliera dei Colli-Monaldi Hospital, 80131 Naples, Italy.
  • 5. Department of Advanced Biomedical Sciences, University Federico II, 80131 Naples, Italy.
  • 6. Department of Pharmacy, University Federico II, 80131 Naples, Italy.
  • 7. Department of Public Health, University of Naples Federico II, 80131 Naples, Italy.
  • 8. University of Naples Federico II
  • 9. Microbiology and Virology Unit, Cotugno Hospital, 80131 Naples, Italy.
  • 10. Department of Clinical Medicine and Surgery-Infectious Diseases, University of Naples Federico II, 80131 Naples, Italy.
  • 11. Staff of UNESCO, Chair for Health Education and Sustainable Development, University Federico II, 80131 Naples, Italy.

Description

Polyphenols are the largest class of bioactive compounds in plants, which are synthesized as secondary metabolites. In the last few years, interesting studies have demonstrated the efficacy of polyphenols against coronavirus infections. we conducted a phase II multicentric clinical trial (TAEROVID-19) during the first wave of the COVID-19 pandemic in order to assess the safety and feasibility of Taurisolo® aerosol formulation in hospitalized patients suffering from SARS-CoV-2 pneumonia. we observed a rapid decline of symptoms and a low rate of intensive care in patients treated with Taurisolo®, with a faster decline of symptoms. This is the first trial assessing the safety and feasibility of Taurisolo® aerosol formulation. We could argue that this treatment could act as an add-on therapy in the treatment of COVID-19 patients, owing to both its anti-inflammatory and antioxidant effects. Further controlled trials are needed, which may be of interest to evaluate the compound's efficacy.
Enabled by The Lens

Open Access

Licence Attribution (CC BY)
Publisher Website Access full text